Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Metagenomi, Inc. - Common Stock (NQ: MGX )

1.820 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Metagenomi, Inc. - Common Stock

Peeling Back The Layers: Exploring Metagenomi Through Analyst Insights
Via Benzinga
Unveiling 4 Analyst Insights On Metagenomi
Via Benzinga
Cogent Communications To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
MGX Stock Earnings: Metagenomi Beats EPS, Beats Revenue for Q2 2024
MGX stock results show that Metagenomi beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024
MGX stock results show that Metagenomi missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
This Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It Yet
A bumpy start can't detract from this company's strong balance sheet. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.